Eli Lilly and Co

• Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
• Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch - Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.
• Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite - The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation
• What obesity drugmakers see next in the market: More pills, easier access and drug combinations - CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.
• Here are the 3 big things we're watching in the stock market in the week ahead - The new year on Wall Street officially kicks into high gear this week.
• 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market - Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
• Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient - The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
• We're buying the post-earnings slump in a stock alongside Tim Cook. It's not Apple - We're scooping up shares of struggling company on a confidence-inducing signal from the board of directors that a bottom could be forming.
• Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval - The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.
• Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.